Two-week intervals during omalizumab treatment may provide better symptom control in selected patients with chronic urticaria

The effectiveness of omalizumab in chronic spontaneous urticaria (CSU) and symptomatic dermographism has been demonstrated in many clinical and real-life studies.1,2 A wide range of dosage from 75 mg to 600 mg was applied in these efficiency studies, and it was proved that the drug efficiency was dose dependent and most efficient dosage in CSU is 300 mg/4 wk.1 However, there are also data that suggest increasing the dose or shortening the intervals particularly when the symptoms cannot be controlled,3 but there is still no consensus on this subject.